Home Cart Sign in  
Chemical Structure| 1192171-69-9 Chemical Structure| 1192171-69-9

Structure of Vonafexor
CAS No.: 1192171-69-9

Chemical Structure| 1192171-69-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Vonafexor is a farnesoid X receptor agonist.

Synonyms: EYP001; PLX007

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Vonafexor

CAS No. :1192171-69-9
Formula : C19H15Cl3N2O5S
M.W : 489.76
SMILES Code : O=C(C1=CC2=C(Cl)C(N3CCN(S(=O)(C4=C(Cl)C=CC=C4Cl)=O)CC3)=CC=C2O1)O
Synonyms :
EYP001; PLX007
MDL No. :MFCD32701906
InChI Key :XLGQSYUNOIJBNR-UHFFFAOYSA-N
Pubchem ID :67202717

Safety of Vonafexor

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06425055 Alport Syndrome PHASE2 ACTIVE_NOT_RECRUITING 2025-10-13 Dr Eric Wallace - University o... More >>f Alabama, Birmingham, Alabama, 35294, United States|Dr Anjay Rastogi - UCLA Health, David Geffen School of Medicine, Los Angeles, California, 90095, United States|Dr Arnold Silva - Boise Kidney & Hypertension, Boise, Idaho, 83703, United States|Dr Suneel Udani - NANI Research, Hinsdale, Illinois, 60521, United States|Dr Tingting Li - Washington University, St. Louis, Missouri, 63110, United States|Dr James Simon - Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Dr Ankit Mehta - Renal Disease Research Institute, Dallas, Texas, 75126, United States|Pr Claire Rigothier - CHU De Bordeaux, Bordeaux, 33076, France|Dr Moglie Le Quintrec - Hopital Lapeyronie, Montpellier, 34090, France|Pr. Bertrand Knebelmann - Necker Enfants Malades, Paris, 75015, France|Fundacio Puigvert, Barcelona, 08025, Spain|Hospital Virgen de la Arrixaca, El Palmar, 30120, Spain|Fundacion Jimenez Diaz, Madrid, 28040, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.21mL

2.04mL

1.02mL

20.42mL

4.08mL

2.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories